Raj Prabhakar currently serves as a Vice President Business Development for Celsion Corporation, an oncology drug development company with headquarters in Lawrenceville, NJ. Celsion recently acquired EGEN Inc., an immunotherapy company located in Huntsville, AL.
Currently Raj Prabhakar leads all merger-integration activities in multiple locations after the acquisition of EGEN, Inc, and will manage a portfolio that will focus on gene and immunotherapy with DNA and RNA drug candidates, in additional to existing small molecule oncology candidates. Mr. Prabhakar reports directly to the CEO, and works primary with clinical development and operations teams in a matrix environment.
Prior to the merger, Raj Prabhakar held both corporate and operating roles within Celsion Corporation to develop and commercialize primary liver cancer indication (Hepatocellular Carcinoma), the company's lead drug candidate. These roles involved all aspects of project management and business development, focused on accelerating lead drug candidate from preclinical to commercialization. Mr. Prabhakar also has significant ex-US on-the-ground experience in setting up global clinical trials in multiple countries, sourcing manufacturing (CMC), and partnering for Phase III registration trials.
Currently Raj Prabhakar leads all merger-integration activities in multiple locations after the acquisition of EGEN, Inc, and will manage a portfolio that will focus on gene and immunotherapy with DNA and RNA drug candidates, in additional to existing small molecule oncology candidates. Mr. Prabhakar reports directly to the CEO, and works primary with clinical development and operations teams in a matrix environment.
Prior to the merger, Raj Prabhakar held both corporate and operating roles within Celsion Corporation to develop and commercialize primary liver cancer indication (Hepatocellular Carcinoma), the company's lead drug candidate. These roles involved all aspects of project management and business development, focused on accelerating lead drug candidate from preclinical to commercialization. Mr. Prabhakar also has significant ex-US on-the-ground experience in setting up global clinical trials in multiple countries, sourcing manufacturing (CMC), and partnering for Phase III registration trials.
RSS Feed
